Skip to content
drillr.ai
Sign up

02595.HK

GenFleet Therapeutics (Shanghai) Inc.

HKSE · Healthcare · Biotechnology · CN

HKD 27.50
−0.51%
Ask drillr

  • Aug 26, 2026, 00:22 UTC

    GenFleet Therapeutics announced that its oral KRAS G12D inhibitor GFH375 has entered a Phase II study as first-line treatment for advanced non-small cell lung cancer with KRAS G12D mutation.

    Source:

  • Aug 21, 2026, 04:06 UTC

    GenFleet Therapeutics (B) reported interim results for the six months ended June 2026, with revenue of RMB 42.47 million, down 52.1% year-on-year, and a narrowed net loss of RMB 220 million versus RMB 699 million a year earlier.

    Source:

  • Aug 10, 2026, 00:33 UTC

    GenFleet Therapeutics announced that its oral KRAS G12D inhibitor GFH375 has initiated a registrational Phase III clinical study for non-small cell lung cancer, with the first patient enrolled at Nanjing Drum Tower Hospital.

    Source: